Changzhou Qianhong Biopharma Co Ltd Market Cap ($1.18 Billion)
Market Cap & Net Worth: Changzhou Qianhong Biopharma Co Ltd (002550)
Changzhou Qianhong Biopharma Co Ltd market cap. Changzhou Qianhong Biopharma Co Ltd (SHE:002550) has a market capitalization of $1.18 Billion (CN¥8.06 Billion) as of November 5, 2026. Listed on the SHE stock exchange, this China-based company holds position #7965 globally and #1757 in its home market, demonstrating a 9.57% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Changzhou Qianhong Biopharma Co Ltd's stock price CN¥6.30 by its total outstanding shares 1279800000 (1.28 Billion). Also see Changzhou Qianhong Biopharma Co Ltd cash flow conversion for how efficiently the company converts equity into cash flow.
Changzhou Qianhong Biopharma Co Ltd Market Cap History (2015–2026)
Changzhou Qianhong Biopharma Co Ltd market cap history from 2015 to 2026. Data shows change from $1.66 Billion to $1.18 Billion (-0.40% CAGR). Check 002550 stock price and chart for real-time trading data and today's change.
Changzhou Qianhong Biopharma Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Changzhou Qianhong Biopharma Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Changzhou Qianhong Biopharma Co Ltd equity growth rate to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.94x
Changzhou Qianhong Biopharma Co Ltd's market cap is 0.94 times its annual revenue
Latest Price to Earnings (P/E) Ratio
3.69x
Changzhou Qianhong Biopharma Co Ltd's market cap is 3.69 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.10 Billion | $776.39 Million | $224.46 Million | 1.42x | 4.91x |
| 2017 | $839.80 Million | $1.07 Billion | $183.00 Million | 0.79x | 4.59x |
| 2018 | $596.10 Million | $1.32 Billion | $221.35 Million | 0.45x | 2.69x |
| 2019 | $737.45 Million | $1.68 Billion | $262.56 Million | 0.44x | 2.81x |
| 2020 | $724.38 Million | $1.67 Billion | -$132.02 Million | 0.43x | N/A |
| 2021 | $847.70 Million | $1.87 Billion | $181.08 Million | 0.45x | 4.68x |
| 2022 | $1.12 Billion | $2.30 Billion | $323.41 Million | 0.49x | 3.47x |
| 2023 | $1.08 Billion | $1.81 Billion | $181.86 Million | 0.59x | 5.93x |
| 2024 | $1.16 Billion | $1.53 Billion | $356.03 Million | 0.76x | 3.26x |
| 2025 | $1.47 Billion | $1.57 Billion | $398.80 Million | 0.94x | 3.69x |
Competitor Companies of 002550 by Market Capitalization
Companies near Changzhou Qianhong Biopharma Co Ltd in the global market cap rankings as of November 5, 2026. Also see total assets of Changzhou Qianhong Biopharma Co Ltd for a full breakdown of the balance sheet.
Key companies related to Changzhou Qianhong Biopharma Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #514 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #538 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #588 globally with a market cap of $45.79 Billion USD ( CN¥312.89 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #621 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #514 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #538 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $47.80 |
| #588 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.79 Billion | CN¥49.05 |
| #621 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Changzhou Qianhong Biopharma Co Ltd (2015–2026)
Market capitalization of Changzhou Qianhong Biopharma Co Ltd from 2015 to today. Between 2015 and today, Changzhou Qianhong Biopharma Co Ltd's market cap moved from $1.66 Billion to $ 1.18 Billion, with a yearly change of -0.40%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.18 Billion | -19.85% |
| 2025 | CN¥1.47 Billion | +26.77% |
| 2024 | CN¥1.16 Billion | +7.69% |
| 2023 | CN¥1.08 Billion | -4.03% |
| 2022 | CN¥1.12 Billion | +32.54% |
| 2021 | CN¥847.70 Million | +17.02% |
| 2020 | CN¥724.38 Million | -1.77% |
| 2019 | CN¥737.45 Million | +23.71% |
| 2018 | CN¥596.10 Million | -29.02% |
| 2017 | CN¥839.80 Million | -23.78% |
| 2016 | CN¥1.10 Billion | -33.45% |
| 2015 | CN¥1.66 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Changzhou Qianhong Biopharma Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.18 Billion USD |
| MoneyControl | $1.18 Billion USD |
| MarketWatch | $1.18 Billion USD |
| marketcap.company | $1.18 Billion USD |
| Reuters | $1.18 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Changzhou Qianhong Biopharma Co Ltd
Changzhou Qianhong Biopharma CO.,LTD manufactures and distributes polysaccharide and protease drugs in China. The company offers heparin sodium, heparin calcium, enoxaparin sodium, dalteparin sodium, nadroparin calcium, pancreatin, heparinoid API, kallidinogenase, and asparaginase. It also provides low molecular weight heparin, compound digestive enzyme preparations, and health products. In addit… Read more